Mabpharm Limited (2181) Price & Analysis

Q: What was Mabpharm Limited’s price range in the past 12 months?

Mabpharm Limited lowest stock price was HK$0.20 and its highest was HK$0.94 in the past 12 months.

Q: What is Mabpharm Limited’s market cap?

Mabpharm Limited’s market cap is HK$2.19B.

Q: When is Mabpharm Limited’s upcoming earnings report date?

Mabpharm Limited’s upcoming earnings report date is Mar 26, 2026 which is in 98 days.

Q: How were Mabpharm Limited’s earnings last quarter?

Mabpharm Limited released its earnings results on Aug 28, 2025. The company reported HK$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.001.

Q: Is Mabpharm Limited overvalued?

According to Wall Street analysts Mabpharm Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Mabpharm Limited pay dividends?

Mabpharm Limited does not currently pay dividends.

Q: What is Mabpharm Limited’s EPS estimate?

Mabpharm Limited’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Mabpharm Limited have?

Mabpharm Limited has 4,124,080,000 shares outstanding.

Q: What happened to Mabpharm Limited’s price movement after its last earnings report?

Mabpharm Limited reported an EPS of HK$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.351%.

Q: Which hedge fund is a major shareholder of Mabpharm Limited?

Currently, no hedge funds are holding shares in HK:2181

Compare

0 Followers

2181 Stock Chart & Stats

HK$0.53

>-HK$0.01(-1.85%)

At close: Jan 09 4:00 PM EST

HK$0.53

>-HK$0.01(-1.85%)

Day’s Range― - ―

52-Week RangeHK$0.20 - HK$0.94

Previous CloseN/A

Volume6.00K

Average Volume (3M)354.33K

Market Cap

HK$2.19B

Enterprise ValueHK$2.23B

Total Cash (Recent Filing)HK$94.16M

Total Debt (Recent Filing)HK$305.01M

Price to Earnings (P/E)―

Beta1.07

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding4,124,080,000

10 Day Avg. Volume54,400

30 Day Avg. Volume354,333

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)12.19

Price to Sales (P/S)4.20

P/FCF Ratio-17.06

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Mabpharm Limited News

Mabpharm Limited Announces Board and Committee Restructuring

Mabpharm Limited ( ($HK:2181) ) just unveiled an announcement. Mabpharm Limited has announced changes to its board and...

2M ago

2181

Mabpharm Limited Updates Nomination Committee Terms

Mabpharm Limited ( ($HK:2181) ) just unveiled an announcement. Mabpharm Limited has amended the terms of reference for...

2M ago

2181

Mabpharm Limited Reports Strong Interim Financial Results for H1 2025

Mabpharm Limited ( ($HK:2181) ) just unveiled an announcement. Mabpharm Limited announced its interim financial results for the...

4M ago

2181

Mabpharm Limited Schedules Board Meeting for Interim Results

Mabpharm Limited ( ($HK:2181) ) has provided an update. Mabpharm Limited has announced that its board of directors...

4M ago

2181

Mabpharm Limited Announces Unanimous Approval of AGM Resolutions

Mabpharm Limited ( ($HK:2181) ) has shared an update. Mabpharm Limited announced that all proposed resolutions at its...

6M ago

2181

Mabpharm Limited Announces 2025 Annual General Meeting and Share Repurchase Proposal

The latest announcement is out from Mabpharm Limited ( ($HK:2181) ). Mabpharm Limited has announced its upcoming Annual...

8M ago

2181

Mabpharm Limited Reports Significant Revenue Growth Amidst Financial Challenges

Mabpharm Limited ( ($HK:2181) ) has provided an update. Mabpharm Limited reported its financial results for the year...

9M ago

2181

Mabpharm Limited Schedules Board Meeting for Annual Results Review

Mabpharm Limited ( ($HK:2181) ) has provided an announcement. Mabpharm Limited has announced that its board of directors...

9M ago

2181

Mabpharm Gains Approval in Pakistan for Key Drug

Mabpharm Limited (HK:2181) has released an update. Mabpharm Limited has received approval from the Drug Regulatory Authority of...

12M ago

2181

Mabpharm Gains Indonesian Approval for Key Drug

Mabpharm Limited (HK:2181) has released an update. Mabpharm Limited has received approval from the Indonesian National Agency of...

12M ago

2181

2181 FAQ

What was Mabpharm Limited’s price range in the past 12 months?

Mabpharm Limited lowest stock price was HK$0.20 and its highest was HK$0.94 in the past 12 months.

What is Mabpharm Limited’s market cap?

Mabpharm Limited’s market cap is HK$2.19B.

When is Mabpharm Limited’s upcoming earnings report date?

Mabpharm Limited’s upcoming earnings report date is Mar 26, 2026 which is in 98 days.

How were Mabpharm Limited’s earnings last quarter?

Mabpharm Limited released its earnings results on Aug 28, 2025. The company reported HK$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.001.

Is Mabpharm Limited overvalued?

According to Wall Street analysts Mabpharm Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Mabpharm Limited pay dividends?

Mabpharm Limited does not currently pay dividends.

What is Mabpharm Limited’s EPS estimate?

Mabpharm Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mabpharm Limited have?

Mabpharm Limited has 4,124,080,000 shares outstanding.

What happened to Mabpharm Limited’s price movement after its last earnings report?

Mabpharm Limited reported an EPS of HK$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.351%.

Which hedge fund is a major shareholder of Mabpharm Limited?

Currently, no hedge funds are holding shares in HK:2181

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Mabpharm Limited Stock Smart Score

Neutral

Analyst Consensus

Hold

Average Price Target:
― (―)

Technicals

Fundamentals

Return on Equity

-25.72%

Trailing 12-Months

Asset Growth

15.04%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mabpharm Limited

Mabpharm Limited (2181) is a biopharmaceutical company specializing in the research, development, and commercialization of innovative monoclonal antibodies and other biologic therapies. The company operates primarily in the pharmaceutical sector, focusing on oncology and autoimmune diseases, and aims to provide effective treatment options that enhance patient outcomes. Mabpharm's core products include proprietary therapeutic candidates that are in various stages of clinical trials, addressing significant unmet medical needs.